

46,200 Results Any time

Mammalian target of rapamycin inhibitors are associated ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/tri.12372>

Jun 18, 2014 · Calcineurin inhibitors (CNIs) have been associated in a dose-dependent fashion with an increased risk of post-transplant hepatocellular carcinoma (HCC) recurrence. The mammalian target of rapamycin inhibitors (mTORi) (sirolimus/everolimus) might represent an alternative immunosuppressive regimen with antineoplastic effect.

Cited by: 111 Author: Evangelos Cholongitas, Chrysanthi Mamo...

Publish Year: 2014

Management of recurrent hepatocellular carcinoma after ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450191>

May 18, 2015 · Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

Cited by: 11 Author: Kenneth Sh Chok

Publish Year: 2015

Mammalian target of rapamycin inhibitors are associated ...

<https://www.ncbi.nlm.nih.gov/pubmed/24943720>

Calcineurin inhibitors (CNIs) have been associated in a dose-dependent fashion with an increased risk of post-transplant hepatocellular carcinoma (HCC) recurrence. The mammalian target of rapamycin inhibitors (mTORi) (sirolimus/everolimus) might represent an alternative immunosuppressive regimen with antineoplastic effect.

Cited by: 111 Author: Evangelos Cholongitas, Chrysanthi Mamo...

Publish Year: 2014

Mammalian target of rapamycin inhibition in hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243151>


Nov 27, 2014 · Core tip: Advanced hepatocellular carcinoma (HCC) has a poor prognosis with limited therapeutic options. The mammalian target of rapamycin (mTOR) pathway (regulated by mTORC1 and mTORC2) is implicated in HCC pathogenesis. This review examines pre-clinical and clinical data demonstrating that mTORC1 inhibition effectively prevents HCC recurrence post-liver transplantation, ...

Cited by: 34 Author: René E Ashworth, Jennifer Wu

Publish Year: 2014

Hepatocellular Carcinoma

Medical Condition



The most common form of liver cancer often seen in people with chronic liver diseases like cirrhosis.

- Rare (Fewer than 200,000 cases per year in US)
- May be preventable by vaccine
- Often requires lab test or imaging
- Treatment from medical professional advised
- Can last several months or years

Caused mainly due to the chronic infection of the liver or DNA mutation of the liver cells. Characterized by unexplained weight loss, upper abdominal pain and yellowing of the skin. Treatment options include hepatectomy, target drug delivery and the use of radiation to kill the cancerous cells.

Symptoms

The early stages of the disease do not present any symptoms but in the later stages the symptoms which are noted are as follows:

- Upper abdominal pain

6 **Name of Journal:** *World Journal of Gastrointestinal Surgery*

Manuscript NO: 53783

Manuscript Type: ORIGINAL ARTICLE

Retrospective Cohort Study

**Mammalian target of rapamycin inhibitors after post-transplant
hepatocellular carcinoma recurrence: Is it too late?**

Au KP *et al.* mTOR inhibitor for post-transplant HCC recurrence

Kin Pan Au, Kenneth Siu Ho Chok

Abstract

BACKGROUND

Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce the risk of tumour recurrence after liver transplantation for hepatocellular carcinoma (HCC). However, its role in established post-transplant HCC recurrence is uncertain.

AIM

Match Overview

1	Internet 18 words crawled on 26-Dec-2019 www.bjcv.s.org	1%
2	Internet 16 words crawled on 29-Nov-2016 austinpublishinggroup.com	1%
3	Internet 14 words crawled on 13-Feb-2020 www.researchsquare.com	1%
4	Crossref 13 words J. D. Hayden, J. C. Myers, G. G. Jamieson. "Illness behavic ... and laparoscopic antireflux surgery: tailoring the wrap to suit	1%
5	Crossref 12 words Campistol, Josep M., Valentan Cuervas-Mons, Nicolas Mani to, Luis Almenar, Manuel Arias, Fernando Casafont, Domingo	<1%
6	Internet 12 words crawled on 05-Oct-2019 f6publishing.blob.core.windows.net	<1%

Mammalian target of rapamycin inhibitors after post-tr



ALL

IMAGES

VIDEOS

54,600 Results

Any time ▾

Mammalian target of rapamycin inhibitors are associated ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/tri.12372>

Calcineurin **inhibitors** (CNIs) have been associated in a dose-dependent fashion with an increased risk of **post-transplant hepatocellular carcinoma (HCC) recurrence**. The **mammalian target of rapamycin inhibitors** (mTORi) (sirolimus/everolimus) might represent an alternative immunosuppressive regimen with antineoplastic effect.

Cited by: 118 **Author:** Evangelos Cholongitas, Chrysanthi Ma...

Publish Year: 2014

Mammalian target of rapamycin inhibitors are associated ...

<https://www.ncbi.nlm.nih.gov/pubmed/24943720>

Calcineurin **inhibitors** (CNIs) have been associated in a dose-dependent fashion with an increased risk of **post-transplant hepatocellular carcinoma (HCC) recurrence**. The **mammalian target of rapamycin inhibitors** (mTORi) (sirolimus/everolimus) might represent an alternative immunosuppressive regimen with antineoplastic effect.

Cited by: 118 **Author:** Evangelos Cholongitas, Chrysanthi Ma...

Publish Year: 2014

Mammalian target of rapamycin inhibition in hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243151>

Nov 27, 2014 · Core tip: Advanced **hepatocellular carcinoma** (HCC) has a poor prognosis with limited therapeutic options. The **mammalian target of rapamycin** (mTOR) pathway (regulated by mTORC1 and mTORC2) is implicated in HCC pathogenesis. This review examines pre-clinical and clinical data demonstrating that mTORC1 inhibition effectively prevents HCC **recurrence** post ...

Cited by: 53 **Author:** René E Ashworth, Jennifer Wu

Publish Year: 2014



Mammalian target of rapamycin inhibitors after post-tra



ALL IMAGES VIDEOS

54,500 Results Any time

Mammalian target of rapamycin inhibitors are associated ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/tri.12372>

Calcineurin inhibitors (CNIs) have been associated in a dose-dependent fashion with an increased risk of post-transplant hepatocellular carcinoma (HCC) recurrence. The mammalian target of rapamycin inhibitors (mTORi) (sirolimus/everolimus) might represent an alternative immunosuppressive regimen with antineoplastic effect.

Cited by: 118 Author: Evangelos Cholongitas, Chrysanthi Mam...
Publish Year: 2014

Mammalian target of rapamycin inhibitors are associated ...

<https://www.ncbi.nlm.nih.gov/pubmed/24943720>

Calcineurin inhibitors (CNIs) have been associated in a dose-dependent fashion with an increased risk of post-transplant hepatocellular carcinoma (HCC) recurrence. The mammalian target of rapamycin inhibitors (mTORi) (sirolimus/everolimus) might represent an alternative immunosuppressive regimen with antineoplastic effect.

Cited by: 118 Author: Evangelos Cholongitas, Chrysanthi Mam...
Publish Year: 2014

Mammalian target of rapamycin inhibition in hepatocellular